Skip Navigation


Carcinogenesis Advance Access originally published online on November 28, 2005
Carcinogenesis 2006 27(4):766-771; doi:10.1093/carcin/bgi295
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/4/766    most recent
bgi295v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ma, H.
Right arrow Articles by Shen, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ma, H.
Right arrow Articles by Shen, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population

Hongxia Ma 1, 2, {dagger}, Zhibin Hu 1, 2, {dagger}, Xiangjun Zhai 2, Shui Wang 3, Xuechen Wang 4, Jianwei Qin 5, Wenseng Chen 2, Guangfu Jin 1, 2, Jiyong Liu 2, Jun Gao 2, Xinru Wang 1, 2, *, Qingyi Wei 6 and Hongbing Shen 1, 2, *

1 Laboratory of Reproductive Medicine, 2 Department of Epidemiology and Biostatistics, Nanjing Medical University, 3 Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, 4 Department of General Surgery, Nanjing Gulou Hospital, 5 Department of General Surgery, Jiangsu Cancer Hospital, Nanjing 210009, China and 6 Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA

* To whom correspondence should be addressed at Department of Epidemiology and Biostatistics, Nanjing Medical University School of Public Health, 140 Hanzhong Road, Nanjing 210029, China. Tel/Fax:+86 25 868 62756; Email: hbshen{at}njmu.edu.cn; xrwang{at}njmu.edu.cn

p53-binding protein 1 (P53BP1), a central transducer of DNA-damage signals to p53, is required for both intra-S-phase and G2-M checkpoints, suggesting that these two proteins may work together in the p53-mediated transcriptional activation and DNA damage-repair signaling pathways. Because the p53-binding region of 53BP1 maps to the C-terminal BRCT domains, which are homologous to those found in the breast cancer protein BRCA1, we hypothesized that genetic variation in P53BP1 and p53 may contribute to breast cancer predisposition. To test this hypothesis, we simultaneously genotyped single nucleotide polymorphisms of T-885G, Glu353Asp, and Gln1136Lys in P53BP1 and Arg72Pro in p53 in a case–control study of 404 breast cancer cases and 472 cancer-free controls. We found that the P53BP1 variant genotypes (alleles) of T-885G and Gln1136Lys were associated with a significantly increased risk of breast cancer among p53 Pro/Pro carriers (OR = 2.36, 95% CI 1.16–4.83 for –885TG/GG; OR = 2.24, 95% CI 1.15–4.37 for 1136Gln/Lys + Lys/Lys and OR = 2.82, 95% CI 1.15–6.94 for >4 variant alleles of these 3 loci). In addition, the variant genotypes of above 3 loci of P53BP1 were significantly associated with elevated risk of progesterone receptor (PR) negative breast cancer, and the T-885G and Gln1136Lys with estrogen receptor (ER) negative breast cancer. Furthermore, we found a significant gene-gene interaction between P53BP1 Gln1136Lys and p53 Arg72Pro variants in relation to breast cancer, and the OR of interaction for the presence of both P53BP1 1136Gln/Lys + Lys/Lys and p53 72Arg/Pro + Pro/Pro genotypes was 1.93 (95% CI 1.06–3.52) (P = 0.031 for interaction). These findings indicate that the SNPs in P53BP1 and p53 jointly contribute to breast cancer risk, particularly ER (–) or PR (–) breast cancer, and the p53 Arg72Pro polymorphism may serve as a risk modifier. Further functional studies are needed to confirm our findings.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. Chen, Z. Hu, L.-E Wang, W. Zhang, A. K. El-Naggar, E. M. Sturgis, and Q. Wei
Polymorphic TP53BP1 and TP53 Gene Interactions Associated with Risk of Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res., July 15, 2007; 13(14): 4300 - 4305.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.